BioTelemetry (BEAT) Tops Q1 EPS by 10c

BioTelemetry (NASDAQ: BEAT) reported Q1 EPS of $0.20, $0.10 better than the analyst estimate of $0.10. Revenue for the quarter came in at $48.6 million versus the consensus estimate of $46.54 million.

For earnings history and earnings-related data on BioTelemetry (BEAT) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• BofA lists top 5 themes driving next $1tn in incremental semi sales